Qiao Xuan, Guo Shuang, Meng Zhiyun, Gan Hui, Wu Zhuona, Sun Yunbo, Liu Shuchen, Dou Guifang, Gu Ruolan
Graduate Collaborative Training Base of Academy of Military Medical Sciences, Hengyang Medical School, University of South China, Hengyang, China.
Beijing Institute of Radiation Medicine, Beijing, China.
Front Pharmacol. 2025 Mar 12;16:1549808. doi: 10.3389/fphar.2025.1549808. eCollection 2025.
DR5, a receptor with the highest affinity for TRAIL under physiological conditions, selectively induces apoptosis in specific target cells such as tumor and aberrant immune cells, while minimally affecting normal cells. The TRAIL-DR5 signaling pathway is a crucial regulatory mechanism when the body responds to various exogenous interference factors, including viruses, chemicals, and radiation. This pathway plays a vital role in maintaining physiological homeostasis and in the pathological development of various diseases. Different modulations of DR5, such as upregulation, activation, and antagonism, hold significant potential for therapeutic applications in tumors, cardiovascular diseases, autoimmune diseases, viral infections, and radiation injuries. This article provides an overview of the current research progress on DR5, including the status and prospects of its clinical applications.
DR5是在生理条件下对TRAIL具有最高亲和力的受体，可选择性地诱导肿瘤和异常免疫细胞等特定靶细胞凋亡，同时对正常细胞影响极小。TRAIL-DR5信号通路是机体对包括病毒、化学物质和辐射在内的各种外源性干扰因素作出反应时的关键调节机制。该通路在维持生理稳态以及各种疾病的病理发展中起着至关重要的作用。对DR5的不同调节，如上调、激活和拮抗，在肿瘤、心血管疾病、自身免疫性疾病、病毒感染和辐射损伤的治疗应用中具有巨大潜力。本文概述了DR5的当前研究进展，包括其临床应用的现状和前景。
